D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea · Delayed Price · Currency is KRW 40,150
-2,700 (-6.30%)
Oct 12, 2026, 3:30 PM KST
D&D Pharmatech Revenue
D&D Pharmatech had revenue of 662.06M KRW in the quarter ending June 30, 2026, a decrease of -28.39%. This brings the company's revenue in the last twelve months to 2.75B, down -70.53% year-over-year. In the year 2025, D&D Pharmatech had annual revenue of 4.30B, down -62.42%. That makes D&D Pharmatech the 42,311th largest company in the world by revenue and 2,563rd in South Korea.
Revenue (ttm)
2.75B
Revenue Growth
-70.53%
P/S Ratio
669.13
Revenue / Employee
110.02M
Employees
25
Market Cap
1.84T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.30B | -7.14B | -62.42% |
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% |
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% |
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% |
| Dec 31, 2021 | 1.36B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.31T |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| Komipharm International | 53.02B |
| ABL Bio | 34.28B |
| Pharmicell | 23.94B |
| OliX Pharmaceuticals | 13.64B |